Camp4 Therapeutics (CAMP) Interest Coverage Ratio (2023 - 2024)
Camp4 Therapeutics recorded quarterly Interest Coverage Ratio of 96.79 in Q4 2024, up 144.4% quarter-over-quarter from 218.0 in Q3 2024, and up 159.61% year-over-year from 37.28 in Q1 2024.
Camp4 Therapeutics' Interest Coverage Ratio history runs 2 years deep, the most recent figure standing at 96.79 for Q4 2024.
- In Q4 2024, Interest Coverage Ratio rose 159.61% year-over-year to 96.79; the TTM figure through Sep 2025 stood at 371.12 (up 202.44% YoY), while the FY2025 annual figure was 273.72, up 82.99% from the prior year.
- Interest Coverage Ratio came in at 96.79 for Q4 2024 at Camp4 Therapeutics, up from 218.0 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 96.79 in Q4 2024 to a low of 262.51 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 96.79 |
| Sep 30, 2024 | -218.00 |
| Dec 31, 2023 | -162.36 |
| Sep 30, 2023 | -262.51 |